to IMGT/mAb-DB
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF

IMGT/mAb-DB ID 1106
INN cilgavimab
INN Number 11777
INN Prop. List 124 (2020)
INN Rec. List 85 (2021)
Common name AZD1061, COV2-2130, 2130, AZD7442
Proprietary name EVUSHELD™ (combination of cilgavimab and tixagevimab)
Species Homo sapiens
IMGT receptor type IG
Format (legend)
Receptor identification IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB 11777
Specificity target name and species Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S) glycoprotein receptor binding domain (RBD) [Homo sapiens]
Development Technology
Origin clone species
Origin clone name

Company AstraZeneca (London UK)
Expression system CHO (Chinese Hamster Ovary) cells
Application Therapeutic
Clinical domain Infectiology
Mechanism of action
Clinical indication Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
Development status Phase I
Regulatory agency status and year
  • FDA approval August 12, 2021

Clinical trials
Authority decisions
    External links
    IMGT notes
    • WHO Drug Information, Vol. 34, No. 3, 2020. Proposed INN List 124 – COVID-19 (special edition) (9 October 2020) pages 642-669. Proposed INN List 124 (19 December 2020, published on 22 January 2021) pages 929-1102.
    • On August 12, 2021, Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of tixagevimab with cilgavimab as pre-exposure prophylaxis for prevention of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals. Press release. Letter of authorization.
      Format legend:

      © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
      European Commission umontpellier CNRS